PT-141 (Bremelanotide)
The one compound in this category that acts on the brain rather than on blood flow — and works for women as well as men.
Bremelanotide, a melanocortin receptor agonist studied in phase 3 clinical trials for low sexual desire in women. Acts in the brain rather than on the vascular system.
- Also known as
- Bremelanotide; Vyleesi
- Class
- Melanocortin receptor agonist acting in the brain
- Evidence
- Approved medicine
- FDA
- Approved (2019) for low sexual desire in premenopausal women
- WADA 2026
- Not named
Concentrations · 1 vial
R 45010mg selected — in stock and shipping now.
About PT-141 (Bremelanotide)
PT-141, or bremelanotide, works on melanocortin receptors in the central nervous system. That is the whole point of it. The familiar erectile dysfunction drugs are vasodilators: they act on blood flow and do nothing for desire. PT-141 acts upstream of that, on arousal itself, which is why it is researched in people for whom the vascular drugs either do not work or do not address the actual problem.
It is also the reason PT-141 is one of the few compounds in the category with a meaningful research base in women. Bremelanotide has been through clinical trials for hypoactive sexual desire disorder in premenopausal women and was approved in the United States on that basis — an unusual level of evidence for anything in a research peptide catalogue.
Specifications
Evidence level: Approved medicine · FDA-approved in 2019 as Vyleesi, for low sexual desire in premenopausal women.
- Formula
- C50H68N14O10 PubChem ↗
- Molecular weight
- 1025.2 g/mol
- CAS number
- 189691-06-3
What it’s researched for
Research context, not medical advice. Everything we sell is supplied for research purposes.
Arousal and desire
Acting on melanocortin receptors in the central nervous system rather than on vascular tissue, which is what makes it applicable to desire rather than only to function.
Men and women
One of the few compounds here with a clinical research base in both, and the only one approved anywhere specifically for desire in women.
Non-vascular mechanism
Researched in people for whom the PDE5 inhibitors are unsuitable or ineffective, because it does not act on the same pathway.
What the research does not show
The limits of the evidence, stated as plainly as the findings.
- An approved use in men. Earlier trials included men, but the approval covers premenopausal women only.
- That a research vial is the same as the registered medicine. It is a different, unregistered product.
Reconstitution and storage
The 10mg vial with 2 mL of bacteriostatic water gives 5mg/mL. Unopened vials are stable at room temperature in transit but belong in a fridge once they arrive, and out of a parked car in a Highveld summer.
Questions we get about PT-141 (Bremelanotide)
Sources
- Kingsberg SA, Clayton AH, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 2019.
- Pfaus JG, Shadiack A, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2004.
- US Food and Drug Administration. VYLEESI (bremelanotide) prescribing information. FDA label, 2019.
Often bought with it
Order PT-141 (Bremelanotide) in South Africa
Everything ships from Johannesburg, nationwide. Add it to your order slip, send the slip on WhatsApp, and we’ll confirm stock, pricing and delivery before you pay a cent.